Downs Syndrome Screening Flashcards
Down’s syndrome
Trisomy 21
Gives dysmorphic features
Purpose of Down’s syndrome screening
Decide which women should receive more invasive tests to establish a definitive diagnosis
What does a Down’s syndrome screening include
USS measurements from the fetus - nuchal translucency
Mother’s age and blood results:
- beta-HCG– a higher result indicates a greater risk
- Pregnancy‑associated plasma protein‑A (PAPPA) – a lower result indicates a greater risk
Combined Test
First line and the most accurate screening test
Performed between 11 and 14 weeks gestation
Ultrasound - nuchal translucency
Maternal blood tests
Nuchal translucency
Nuchal thickness > 6mm - higher risk of Down’s syndrome
Beta HCG
Higher result indicates a greater risk
Pregnancy‑associated plasma protein‑A (PAPPA)
Lower result indicates a greater risk
Triple Test
Between 14 and 20 weeks gestation.
Maternal blood tests:
Beta-HCG – a higher result indicates greater risk
Alpha-fetoprotein (AFP) – a lower result indicates a greater risk
Serum oestriol (female sex hormone) – a lower result indicates a greater risk
When is a combined test performed
11 - 14 weeks
When is a triple test performed
If a combined test has not been performed
14 - 20 weeks
When is a Quadruple Test performed
14 - 20 weeks gestation
What does a quadruple test involve
Beta-HCG – a higher result indicates greater risk
Alpha-fetoprotein (AFP) – a lower result indicates a greater risk
Serum oestriol (female sex hormone) – a lower result indicates a greater risk
Inhibin - A - a higher inhibin A indicates a greater risk
Antenatal Down’s syndrome screening risk implications
When the risk of Down’s is greater than 1 in 150 the woman is offered amniocentesis or chorionic villus sampling
Chorionic villus sampling (CVS)
USS - guided biopsy of the placental tissue.
When is chorionic villus sampling used?
When testing is done earlier in pregnancy (before 15 weeks)